Study of ALTO-101 in Patients With Schizophrenia
NCT06502964
This study is recruiting at 13 US sites in 7 states, according to its ClinicalTrials.gov record last updated .
Summary
This is a Phase 2, double-blind, placebo-controlled, two-way crossover study to compare the efficacy of ALTO-101T versus placebo in change in electroencephalogram (EEG) cognitive processing markers and measures of cognition. Additional goals are to assess pharmacokinetic (PK), safety, and tolerability of the recently developed ALTO-101T transdermal delivery system (TDS) formulation in a patient population.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Schizophrenia
- Cognitive Impairment
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 21 to 55 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Alto Neuroscience
- Last updated on ClinicalTrials.gov
- December 26, 2025
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 4
- Site 5038 · Garden Grove, CA
- Site 5063 · Los Angeles, CA
- Site 5106 · Orange, CA
- Site 5035 · Walnut Creek, CA
Florida · 2
- Site 5060 · Hollywood, FL
- Site 5015 · Tampa, FL
Georgia · 1
- Site 5064 · Snellville, GA
Illinois · 1
- Site 5056 · Chicago, IL
Maryland · 1
- Site 5062 · Gaithersburg, MD
Massachusetts · 1
- Site 5124 · Belmont, MA
New York · 3
- Site 5077 · New York, NY
- Site 5108 · New York, NY
- Site 5126 · White Plains, NY
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.